A detailed history of Pro Share Advisors LLC transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 21,904 shares of RVNC stock, worth $56,293. This represents 0.0% of its overall portfolio holdings.

Number of Shares
21,904
Previous 20,095 9.0%
Holding current value
$56,293
Previous $176,000 39.2%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 08, 2024

BUY
$4.65 - $9.31 $8,411 - $16,841
1,809 Added 9.0%
21,904 $107,000
Q4 2023

Feb 14, 2024

BUY
$5.81 - $11.2 $20,387 - $39,300
3,509 Added 21.16%
20,095 $176,000
Q3 2023

Nov 13, 2023

BUY
$11.47 - $25.07 $3,418 - $7,470
298 Added 1.83%
16,586 $190,000
Q2 2023

Aug 10, 2023

BUY
$24.7 - $37.61 $25,811 - $39,302
1,045 Added 6.86%
16,288 $412,000
Q1 2023

May 11, 2023

SELL
$18.36 - $35.27 $35,802 - $68,776
-1,950 Reduced 11.34%
15,243 $490,000
Q4 2022

Feb 02, 2023

BUY
$18.32 - $30.66 $57,451 - $96,149
3,136 Added 22.31%
17,193 $317,000
Q3 2022

Nov 04, 2022

BUY
$14.33 - $28.47 $7,394 - $14,690
516 Added 3.81%
14,057 $379,000
Q2 2022

Aug 01, 2022

SELL
$11.52 - $20.4 $80,812 - $143,106
-7,015 Reduced 34.13%
13,541 $187,000
Q1 2022

May 10, 2022

SELL
$12.36 - $20.31 $60,180 - $98,889
-4,869 Reduced 19.15%
20,556 $400,000
Q4 2021

Feb 08, 2022

BUY
$12.46 - $27.87 $13,519 - $30,238
1,085 Added 4.46%
25,425 $414,000
Q3 2021

Nov 12, 2021

SELL
$25.78 - $33.21 $173,293 - $223,237
-6,722 Reduced 21.64%
24,340 $678,000
Q2 2021

Aug 13, 2021

BUY
$26.8 - $31.84 $117,518 - $139,618
4,385 Added 16.44%
31,062 $921,000
Q1 2021

May 14, 2021

BUY
$24.03 - $29.97 $59,282 - $73,935
2,467 Added 10.19%
26,677 $746,000
Q4 2020

Feb 09, 2021

BUY
$23.41 - $28.34 $137,463 - $166,412
5,872 Added 32.02%
24,210 $686,000
Q3 2020

Nov 13, 2020

BUY
$23.23 - $34.3 $34,937 - $51,587
1,504 Added 8.93%
18,338 $461,000
Q2 2020

Aug 03, 2020

BUY
$12.6 - $26.55 $84,571 - $178,203
6,712 Added 66.31%
16,834 $411,000
Q1 2020

May 15, 2020

SELL
$12.46 - $27.81 $71,657 - $159,935
-5,751 Reduced 36.23%
10,122 $150,000
Q4 2019

Feb 12, 2020

SELL
$11.66 - $20.15 $12,604 - $21,782
-1,081 Reduced 6.38%
15,873 $258,000
Q3 2019

Nov 12, 2019

BUY
$10.22 - $14.5 $602 - $855
59 Added 0.35%
16,954 $220,000
Q2 2019

Aug 13, 2019

SELL
$10.67 - $15.49 $23,676 - $34,372
-2,219 Reduced 11.61%
16,895 $219,000
Q1 2019

May 15, 2019

BUY
$15.4 - $20.39 $48,048 - $63,616
3,120 Added 19.51%
19,114 $301,000
Q4 2018

Feb 14, 2019

SELL
$18.06 - $24.96 $55,697 - $76,976
-3,084 Reduced 16.17%
15,994 $322,000
Q3 2018

Nov 14, 2018

SELL
$23.55 - $30.1 $16,555 - $21,160
-703 Reduced 3.55%
19,078 $474,000
Q2 2018

Aug 13, 2018

SELL
$27.45 - $33.35 $14,438 - $17,542
-526 Reduced 2.59%
19,781 $543,000
Q1 2018

May 14, 2018

BUY
$29.15 - $37.4 $6,937 - $8,901
238 Added 1.19%
20,307 $625,000
Q4 2017

Feb 14, 2018

BUY
$24.55 - $36.3 $28,748 - $42,507
1,171 Added 6.2%
20,069 $717,000
Q3 2017

Nov 13, 2017

BUY
$22.55 - $28.1 $31,051 - $38,693
1,377 Added 7.86%
18,898 $521,000
Q2 2017

Aug 11, 2017

BUY
N/A
17,521
17,521 $463,000

Others Institutions Holding RVNC

About Revance Therapeutics, Inc.


  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.